Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acasti Pharma
(NQ:
ACST
)
2.365
-0.085 (-3.46%)
Streaming Delayed Price
Updated: 2:42 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Acasti Pharma
Acasti Pharma Reports Third Quarter 2023 Operational Results
February 14, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
January 25, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
January 24, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
January 17, 2023
Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage...
Via
Newsfile
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
January 13, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
January 05, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
December 28, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
December 22, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma Reports Second Quarter 2023 Operational Results
November 14, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma to Present at Q4 Investor Summit
November 09, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
November 07, 2022
Call to be held on Monday, November 14th at 1:00 PM Eastern Time
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma Inc. (NASDAQ:ACST) (TSX.V:ACST) Featured in Coverage of Investor Summit Group’s Q4 Event
November 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Acasti Announces Court Dismissal of Stockholder Litigation
September 30, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
September 29, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast
September 21, 2022
Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),...
Via
Newsfile
Exposures
Product Safety
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
July 27, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast
July 07, 2022
Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),...
Via
Newsfile
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
May 16, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public...
From
MicroCap Rodeo
Via
AccessWire
Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
May 12, 2022
LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present...
From
Acasti Pharma Inc.
Via
AccessWire
Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast
February 22, 2022
Phoenix, Arizona--(Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"),...
Via
Newsfile
ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST
May 12, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acasti Pharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Acasti Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ACST
May 07, 2021
From
Halper Sadeh LLP
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.